Symbols / EQ $1.99 +1.02%
EQ Chart
About
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 121.18M |
| Enterprise Value | 88.80M | Income | -24.42M | Sales | 4.39M |
| Book/sh | 0.51 | Cash/sh | 0.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 35 | IPO | — |
| P/E | — | Forward P/E | -3.57 | PEG | — |
| P/S | 27.59 | P/B | 3.90 | P/C | — |
| EV/EBITDA | -3.66 | EV/Sales | 20.22 | Quick Ratio | 10.74 |
| Current Ratio | 10.85 | Debt/Eq | 2.41 | LT Debt/Eq | — |
| EPS (ttm) | -0.58 | EPS next Y | -0.56 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 16:00 | ROA | -44.17% |
| ROE | -90.24% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -5.55% | Profit Margin | 0.00% | Shs Outstand | 60.89M |
| Shs Float | 29.04M | Short Float | 4.12% | Short Ratio | 3.94 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.27 |
| Beta | 1.83 | Avg Volume | 629.76K | Volume | 230.06K |
| Target Price | $3.33 | Recom | None | Prev Close | $1.97 |
| Price | $1.99 | Change | 1.02% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.33
Mean price target
2. Current target
$1.99
Latest analyst target
3. DCF / Fair value
$-3.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.99
Low
$1.00
High
$5.00
Mean
$3.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-28 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2024-11-01 | down | Jones Trading | Buy → Hold | — |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-12-26 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2023-11-13 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-08-14 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-05-01 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-03-24 | main | Stifel | — → Buy | $7 |
| 2023-02-08 | main | SVB Leerink | — → Outperform | $7 |
| 2022-09-27 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2022-09-08 | main | SVB Leerink | — → Outperform | $12 |
| 2022-03-24 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2022-01-05 | main | SVB Leerink | — → Outperform | $14 |
| 2021-09-15 | init | Cantor Fitzgerald | — → Overweight | $14 |
| 2021-03-03 | init | JonesTrading | — → Buy | $14 |
News
RSS: Latest EQ news- Equillium (NASDAQ:EQ) COO Sells $362,438.00 in Stock - MarketBeat hu, 12 Mar 2026 00
- EQ Resources Seeks ASX Quotation for 13.7 Million New Shares - TipRanks Wed, 11 Mar 2026 23
- EQ Resources Issues New Shares Following Option Exercises and Confirms Regulatory Compliance - TipRanks Wed, 11 Mar 2026 23
- EQ Resources A$0.302 intraday (EQR.AX ASX) 09 Mar 2026: Earnings to guide market - Meyka Mon, 09 Mar 2026 04
- The Best Equity ETFs - Morningstar Mon, 02 Mar 2026 08
- $EQ stock is up 23% today. Here's what we see in our data. - Quiver Quantitative Wed, 10 Dec 2025 08
- Shareholder services - Bristol Myers Squibb Wed, 14 May 2025 07
- EQ and Raymond James Partner to Offer Clients a Comprehensive Equity Stock Plan Solution - Yahoo Finance Wed, 15 Oct 2025 07
- Equillium (NASDAQ:EQ) Stock Rating Upgraded by Zacks Research - MarketBeat Sat, 28 Feb 2026 08
- EQ Resources Issues New Shares via Option Exercises Under Cleansing Notice - TipRanks ue, 10 Mar 2026 22
- Equillium (NASDAQ:EQ) COO Sells $327,249.12 in Stock - MarketBeat Mon, 23 Feb 2026 08
- EQ Resources Shares Surge After Key Index Inclusion - TipRanks Wed, 11 Mar 2026 00
- Short Interest in Equillium, Inc. (NASDAQ:EQ) Expands By 47.0% - MarketBeat Sun, 01 Mar 2026 12
- EQ Resources Seeks ASX Quotation for 5.5 Million New Shares - TipRanks ue, 10 Mar 2026 22
- EQ Resources Issues 38 Million Shares via Option Exercises and Confirms Compliance - TipRanks Sun, 08 Mar 2026 23
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 185937 | 328104 | — | Sale at price 1.74 - 1.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 1 | 185937 | 141750 | — | Conversion of Exercise of derivative security at price 0.73 - 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2026-02-19 00:00:00 | D |
| 2 | 6533 | 8428 | — | Sale at price 1.29 per share. | TOM PENNY | Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 100000 | 150000 | — | Sale at price 1.50 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 4 | 100000 | 78500 | — | Conversion of Exercise of derivative security at price 0.78 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-23 00:00:00 | D |
| 5 | 35704 | 47486 | — | Sale at price 1.31 - 1.34 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 8098 | 7696 | — | Sale at price 0.95 - 0.98 per share. | ZEDELMAYER CHRISTINE | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 7 | 10000 | 6500 | — | Sale at price 0.65 per share. | KEYES JASON A | Chief Financial Officer | — | 2025-01-23 00:00:00 | I |
| 8 | 15000 | 10518 | — | Stock Award(Grant) at price 0.70 per share. | KEYES JASON A | Chief Financial Officer | — | 2024-12-10 00:00:00 | D |
| 9 | 10000 | 7000 | — | Sale at price 0.70 per share. | KEYES JASON A | Chief Financial Officer | — | 2024-11-14 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -7.57M | -12.14M | -38.21M | -37.91M |
| TotalUnusualItems | 0.00 | -23.05M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -23.05M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.07M | -13.34M | -62.43M | -39.05M |
| ReconciledDepreciation | 137.00K | 126.00K | 118.00K | 72.00K |
| EBITDA | -7.57M | -12.14M | -61.26M | -37.91M |
| EBIT | -7.71M | -12.26M | -61.38M | -37.98M |
| NetInterestIncome | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpense | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncome | 1.38M | 2.33M | 420.00K | 57.00K |
| NormalizedIncome | -8.07M | -13.34M | -39.38M | -39.05M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.07M | -13.34M | -62.43M | -39.05M |
| TotalExpenses | 49.36M | 50.61M | 54.79M | 37.79M |
| TotalOperatingIncomeAsReported | -8.27M | -14.52M | -62.08M | -37.79M |
| DilutedAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| BasicAverageShares | 35.36M | 34.73M | 33.73M | 28.81M |
| DilutedEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| BasicEPS | -0.23 | -0.38 | -1.85 | -1.36 |
| DilutedNIAvailtoComStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeCommonStockholders | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncome | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeIncludingNoncontrollingInterests | -8.07M | -13.34M | -62.43M | -39.05M |
| NetIncomeContinuousOperations | -8.07M | -13.34M | -62.43M | -39.05M |
| TaxProvision | 361.00K | 580.00K | 0.00 | |
| PretaxIncome | -7.71M | -12.76M | -62.43M | -39.05M |
| OtherIncomeExpense | -818.00K | -76.00K | -22.77M | -250.00K |
| OtherNonOperatingIncomeExpenses | -818.00K | -76.00K | 281.00K | -250.00K |
| SpecialIncomeCharges | 0.00 | -23.05M | 0.00 | |
| OtherSpecialCharges | 23.05M | |||
| NetNonOperatingInterestIncomeExpense | 1.38M | 1.84M | -633.00K | -1.02M |
| InterestExpenseNonOperating | 0.00 | 491.00K | 1.05M | 1.07M |
| InterestIncomeNonOperating | 1.38M | 2.33M | 420.00K | 57.00K |
| OperatingIncome | -8.27M | -14.52M | -39.03M | -37.79M |
| OperatingExpense | 49.36M | 50.61M | 54.79M | 37.79M |
| ResearchAndDevelopment | 37.43M | 37.04M | 37.55M | 26.38M |
| SellingGeneralAndAdministration | 11.94M | 13.57M | 17.24M | 11.41M |
| GeneralAndAdministrativeExpense | 11.94M | 13.57M | 17.24M | 11.41M |
| OtherGandA | 11.94M | 13.57M | 17.24M | 11.41M |
| TotalRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| OperatingRevenue | 41.09M | 36.08M | 15.76M | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 35.56M | 35.25M | 34.41M | 29.46M |
| ShareIssued | 35.56M | 35.25M | 34.41M | 29.46M |
| TotalDebt | 384.00K | 824.00K | 10.19M | 11.79M |
| TangibleBookValue | 19.06M | 22.57M | 31.94M | 66.50M |
| InvestedCapital | 19.06M | 22.57M | 40.90M | 76.68M |
| WorkingCapital | 18.62M | 21.78M | 44.70M | 74.45M |
| NetTangibleAssets | 19.06M | 22.57M | 31.94M | 66.50M |
| CapitalLeaseObligations | 384.00K | 824.00K | 1.23M | 1.61M |
| CommonStockEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| TotalCapitalization | 19.06M | 22.57M | 35.18M | 75.25M |
| TotalEquityGrossMinorityInterest | 19.06M | 22.57M | 31.94M | 66.50M |
| StockholdersEquity | 19.06M | 22.57M | 31.94M | 66.50M |
| GainsLossesNotAffectingRetainedEarnings | 781.00K | 140.00K | 76.00K | -138.00K |
| OtherEquityAdjustments | 781.00K | 140.00K | 76.00K | -138.00K |
| RetainedEarnings | -193.81M | -185.74M | -172.41M | -109.98M |
| AdditionalPaidInCapital | 212.08M | 208.17M | 204.27M | 176.62M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 2.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 6.54M | 27.96M | 46.48M | 18.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 187.00K | 384.00K | 14.44M | 9.98M |
| NonCurrentDeferredLiabilities | 0.00 | 10.38M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 10.38M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 187.00K | 384.00K | 4.06M | 9.98M |
| LongTermCapitalLeaseObligation | 187.00K | 384.00K | 824.00K | 1.24M |
| LongTermDebt | 3.24M | 8.75M | ||
| CurrentLiabilities | 6.36M | 27.57M | 32.04M | 8.91M |
| CurrentDeferredLiabilities | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDeferredRevenue | 0.00 | 15.73M | 14.70M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 197.00K | 440.00K | 6.12M | 1.80M |
| CurrentCapitalLeaseObligation | 197.00K | 440.00K | 408.00K | 376.00K |
| CurrentDebt | 5.71M | 1.43M | ||
| OtherCurrentBorrowings | 5.71M | 1.43M | ||
| PayablesAndAccruedExpenses | 6.16M | 11.40M | 11.22M | 7.11M |
| CurrentAccruedExpenses | 3.12M | 6.70M | 7.24M | 5.89M |
| InterestPayable | 0.00 | 74.00K | 71.00K | |
| Payables | 3.04M | 4.71M | 3.98M | 1.23M |
| TotalTaxPayable | 365.00K | 0.00 | ||
| IncomeTaxPayable | 365.00K | 0.00 | ||
| AccountsPayable | 2.68M | 4.71M | 3.98M | 1.23M |
| TotalAssets | 25.60M | 50.53M | 78.42M | 85.41M |
| TotalNonCurrentAssets | 626.00K | 1.18M | 1.69M | 2.04M |
| OtherNonCurrentAssets | 70.00K | 104.00K | 153.00K | |
| NetPPE | 626.00K | 1.11M | 1.58M | 1.88M |
| AccumulatedDepreciation | -499.00K | -364.00K | -249.00K | -147.00K |
| GrossPPE | 1.12M | 1.48M | 1.83M | 2.03M |
| Leases | 20.00K | 20.00K | 20.00K | 0.00 |
| OtherProperties | 364.00K | 796.00K | 1.19M | 1.65M |
| MachineryFurnitureEquipment | 741.00K | 659.00K | 620.00K | 384.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 24.98M | 49.35M | 76.73M | 83.37M |
| OtherCurrentAssets | 429.00K | 235.00K | 8.00K | 2.66M |
| PrepaidAssets | 830.00K | 1.96M | 1.59M | 2.66M |
| Receivables | 1.14M | 6.29M | 4.11M | 0.00 |
| OtherReceivables | 178.00K | 497.00K | 269.00K | |
| TaxesReceivable | 966.00K | 2.05M | 1.01M | |
| AccountsReceivable | 0.00 | 3.73M | 2.84M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 22.57M | 40.87M | 71.02M | 80.71M |
| OtherShortTermInvestments | 4.49M | 17.65M | 11.92M | 30.34M |
| CashAndCashEquivalents | 18.09M | 23.22M | 59.11M | 50.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.11M | -21.83M | -9.01M | -32.14M |
| RepurchaseOfCapitalStock | 0.00 | -260.00K | 0.00 | |
| RepaymentOfDebt | 0.00 | -9.13M | -1.43M | |
| IssuanceOfCapitalStock | 0.00 | 29.91M | ||
| CapitalExpenditure | -85.00K | -50.00K | -279.00K | -57.00K |
| InterestPaidSupplementalData | 0.00 | 946.00K | 847.00K | 836.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 580.00K | 0.00 | |
| EndCashPosition | 18.09M | 23.22M | 59.11M | 50.37M |
| BeginningCashPosition | 23.22M | 59.11M | 50.37M | 23.98M |
| EffectOfExchangeRateChanges | -83.00K | -118.00K | 5.00K | -2.00K |
| ChangesInCash | -5.05M | -35.77M | 8.74M | 26.39M |
| FinancingCashFlow | 164.00K | -9.23M | -1.22M | 31.06M |
| CashFlowFromContinuingFinancingActivities | 164.00K | -9.23M | -1.22M | 31.06M |
| ProceedsFromStockOptionExercised | 164.00K | 165.00K | 214.00K | 1.15M |
| NetCommonStockIssuance | 0.00 | -260.00K | 0.00 | 29.91M |
| CommonStockPayments | 0.00 | -260.00K | 0.00 | |
| CommonStockIssuance | 0.00 | 29.91M | ||
| NetIssuancePaymentsOfDebt | 0.00 | -9.13M | -1.43M | |
| NetLongTermDebtIssuance | 0.00 | -9.13M | -1.43M | |
| LongTermDebtPayments | 0.00 | -9.13M | -1.43M | |
| InvestingCashFlow | 13.81M | -4.76M | 18.68M | 27.41M |
| CashFlowFromContinuingInvestingActivities | 13.81M | -4.76M | 18.68M | 27.41M |
| NetInvestmentPurchaseAndSale | 13.90M | -4.71M | 18.26M | 27.46M |
| SaleOfInvestment | 31.50M | 50.00M | 33.23M | 60.45M |
| PurchaseOfInvestment | -17.60M | -54.71M | -14.96M | -32.99M |
| NetBusinessPurchaseAndSale | 0.00 | 700.00K | 0.00 | |
| SaleOfBusiness | 0.00 | 700.00K | 0.00 | |
| NetPPEPurchaseAndSale | -85.00K | -50.00K | -279.00K | -57.00K |
| PurchaseOfPPE | -85.00K | -50.00K | -279.00K | -57.00K |
| OperatingCashFlow | -19.03M | -21.78M | -8.73M | -32.08M |
| CashFlowFromContinuingOperatingActivities | -19.03M | -21.78M | -8.73M | -32.08M |
| ChangeInWorkingCapital | 842.00K | -2.55M | 19.00K | 1.70M |
| ChangeInOtherWorkingCapital | -9.00K | -13.00K | 75.00K | -37.00K |
| ChangeInOtherCurrentLiabilities | -151.00K | |||
| ChangeInOtherCurrentAssets | 114.00K | |||
| ChangeInPayablesAndAccruedExpense | -5.16M | 169.00K | 2.94M | 1.52M |
| ChangeInAccruedExpense | -3.16M | -554.00K | 432.00K | 3.10M |
| ChangeInPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInAccountPayable | -2.00M | 723.00K | 2.51M | -1.58M |
| ChangeInPrepaidAssets | 2.27M | -1.80M | -158.00K | 214.00K |
| ChangeInReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| ChangesInAccountReceivables | 3.73M | -897.00K | -2.84M | 0.00 |
| OtherNonCashItems | -15.73M | -9.17M | 48.33M | 237.00K |
| StockBasedCompensation | 3.75M | 4.00M | 4.84M | 4.41M |
| AmortizationOfSecurities | -754.00K | -914.00K | 127.00K | 314.00K |
| DepreciationAmortizationDepletion | 137.00K | 126.00K | 118.00K | 72.00K |
| DepreciationAndAmortization | 137.00K | 126.00K | 118.00K | 72.00K |
| Depreciation | 137.00K | 126.00K | 118.00K | |
| OperatingGainsLosses | 794.00K | 58.00K | 260.00K | 240.00K |
| NetForeignCurrencyExchangeGainLoss | 794.00K | 58.00K | 260.00K | 240.00K |
| NetIncomeFromContinuingOperations | -8.07M | -13.34M | -62.43M | -39.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for EQ
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|